1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.
Chair and Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, Poland.
Cardiol J. 2023;30(5):832-842. doi: 10.5603/CJ.a2023.0029. Epub 2023 May 11.
Mitral valve dysfunction affects around 2% of the population and its incidence is still increasing, making it the second most common valvular heart disease, after aortic stenosis. Depending on the etiology of the disease, it can be classified into primary or secondary mitral regurgitation. The first line of treatment is optimal medical therapy. If ineffective, mitral valve intervention can be considered. For patients disqualified from surgical treatment, transcatheter edge-to-edge repair with the use of MitraClip may be considered. Over 100,000 MitraClip procedures have been performed which makes this the most established transcatheter technique for the treatment of severe mitral regurgitation. The aim of this review is to discuss the technical details of the MitraClip procedure, clinical evidence regarding the efficacy of MitraClip, complications related to the clip implantation alongside with acute complications based on the currently available evidence and clinical experience.
二尖瓣功能障碍影响约 2%的人群，其发病率仍在上升，使其成为仅次于主动脉瓣狭窄的第二大常见瓣膜性心脏病。根据疾病的病因，可分为原发性或继发性二尖瓣反流。一线治疗是最佳药物治疗。如果无效，可以考虑二尖瓣介入治疗。对于不符合手术治疗的患者，可能会考虑使用 MitraClip 进行经导管瓣环成形术。已经完成了超过 10 万例 MitraClip 手术，使其成为治疗严重二尖瓣反流最成熟的经导管技术。本文旨在讨论 MitraClip 手术的技术细节、MitraClip 疗效的临床证据、基于现有证据和临床经验的与夹子植入相关的并发症以及急性并发症。
